-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, Japanese pharmaceutical company Astellas Pharma announced that its oral non-hormonal treatment of moderate to severe menopausal vasomotor symptoms (VMS) fezolinetant has achieved positive results in two phase 3 phases.
SKYLIGHT 1 and SKYLIGHT 2 are double-blind and placebo-controlled studies.
The results of the trial showed that the two key trials reached 4 main co-endpoints.
In the trial, no more than 2% of the subjects had a serious treatment emergency adverse event (TEAE), and the most common side effect was headache.
Non-hormonal therapy fezolinetant is an oral non-hormonal selective neurokinin 3 receptor (NK3R) antagonist.
This transaction was driven by the results of a phase IIa clinical study of the drug.
Vasomotor symptoms, hot flashes and night sweats related to menopause, are common symptoms of menopausal women.
Hormone therapy is currently the first-line drug choice for women with vasomotor symptoms without contraindications.
In addition to the above two trials, Astellas is also conducting another SKYLIGHT 4 (NCT04003389) trial, which is a 52-week double-blind and placebo-controlled study to study the long-term safety of fezolinetant.
It is worth mentioning that in January last year, Astellas fezolinetant received clinical approval in China for the treatment of moderate to severe vasomotor disease (VMS).
Reference source:
1.
2.
